Items Tagged ‘opdivo’

April 23, 2018

FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer

By

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About Renal Cell Carcinoma Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than […]

View full entry

Tags: atezolizumab, Checkpoint inhibitors Keytruda, durvalumab, Imfinzi, kidney cancer, News, nivolumab, opdivo, pembrolizumab, Renal Cancer, renal cell cancer, Tecentriq


January 9, 2018

FDA Approves Opdivo for Adjuvant Treatment of Melanoma

By

CancerConnect News: The United States Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, Opdivo (nivolumab) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. Opdivo was previously approved for the treatment of patients with unresectable or […]

View full entry

Tags: malignant melanoma, Melanoma, News, nibolumab, opdivo, Precision Cancer Medicine, Yervoy


January 8, 2018

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer

By

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial.1 About Lung Cancer Lung cancer remains the leading cause of cancer-related deaths worldwide. In the […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, opdivo, pembrolizumab, Precision Cancer Medicine, Tecentriq


November 9, 2017

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer

By

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to expand and are associated with improved outcomes. About Renal Cell Carcinoma Renal cell carcinoma accounts for more than 100,000 deaths worldwide each […]

View full entry

Tags: afinitor, checkpoint inhibitor, everolimus, immunotherapy, metastatic kidney cancer, News, opdivo, PD-1, Precision Cancer Medicine, Renal Cancer


October 23, 2017

Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer

By

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior to standard chemotherapy and significantly improves survival. Lung cancer remains the leading cause of cancer-related deaths worldwide. In […]

View full entry

Tags: immunotherapy, keytruda, News, Non-Hodgkin's Lymphoma, non-small cell lung cancer, opdivo, PD-1, Precision Cancer Medicine


October 17, 2017

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

By

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A recently published study has demonstrated that patients with earlier stage III, locally advanced NSCLC may benefit from anther checkpoint inhibitor Imfinzi […]

View full entry

Tags: checkpoint inhibitor, durvalumab, Imfinzi, immunotherapy, keytruda, locally advanced NSCLC, Lung Cancer, News, nivolumab, opdivo, pembrolizumab, Precision Cancer Medicine


October 4, 2017

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), which is […]

View full entry

Tags: 2016, advanced, ESMO, keytruda, Lung Cancer, News, Non-Hodgkin's Lymphoma, nsclc, opdivo, PD-1, pembrolizumab, Tecentriq


September 28, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

By

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European Society for Medical Oncology and published simultaneously in the New England Journal of Medicine. There remains an unmet need for […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, nivolumab, opdivo, Precision Cancer Medicine, Yervoy


April 24, 2015

Opdivo®

By

Class: Biological Therapy Generic Name: Nivolumab Trade Name: Opdivo® For which conditions is this drug approved? Opdivo is approved to treat melanoma that: a) can’t be removed by surgery; or b) metastatic melanoma that’s progressed after treatment with Yervoy® (ipilimumab) or, if BRAF V600 mutation positive, progressed after treatment with a BRAF inhibitor. Opdivo is […]

View full entry

Tags: Biological Therapy, Drug Dictionary, metastatic melanoma, O, opdivo


March 11, 2015

Novel PD-1 Inhibitor Opdivo Approved for Treatment of Lung Cancer

By

The Food and Drug Administration has expanded approval of the PD-1 inhibitor Opdivo® (nivolumab) to include treatment of patients who have metastatic squamous non–small cell lung cancer (NSCLC) that progresses following treatment with platinum-based chemotherapy. Nivolumab belongs to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to […]

View full entry

Tags: FDA approval, immune response, Lung Cancer, Lung Cancer - Non-Small Cell, metastatic squamous non-small cell lung cancer, nsclc, opdivo, PD-1 inhibitor, Recurrent Lung Cancer - Non-Small Cell